CAXTON CORP - Q1 2016 holdings

Add to watchlist

$72.5 Million is the total value of CAXTON CORP's 18 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 50.0% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
SPY BuySPDR S&P 500 ETF TRput$27,783,000
+265.9%
135,186
+262.9%
38.34%
+20.4%
CPXX BuyCELATOR PHARMACEUTICALS INC$25,620,000
+548.0%
2,322,769
+3.4%
35.36%
+113.2%
AGRX BuyAGILE THERAPEUTICS INC$8,873,000
+3843.6%
1,428,871
+6103.0%
12.24%
+1197.1%
SNTA BuySYNTA PHARMACEUTICALS CORP$5,209,000
-31.8%
21,704,847
+0.0%
7.19%
-77.6%
BRKB BuyBERKSHIRE HATHAWAY INC DELcl b new$1,293,000
+533.8%
9,116
+489.7%
1.78%
+108.4%
ACAS SellAMERICAN CAP LTD$1,044,000
+10.4%
68,537
-0.1%
1.44%
-63.7%
IWM NewISHARES TRput$591,000–5,338
+100.0%
0.82%–
CSWI NewCSW INDUSTRIALS INC$344,000–10,906
+100.0%
0.48%–
SCM BuySTELLUS CAP INVT CORP$240,000
+16.5%
23,489
+9.9%
0.33%
-61.7%
CMFN BuyCM FIN INC$237,000
+58.0%
28,220
+87.9%
0.33%
-48.0%
KPTI NewKARYOPHARM THERAPEUTICS INC$221,000–24,829
+100.0%
0.30%–
DOV NewDOVER CORP$211,000–3,285
+100.0%
0.29%–
MCC BuyMEDLEY CAP CORP$179,000
+42.1%
27,093
+62.3%
0.25%
-53.3%
ABUS BuyARBUTUS BIOPHARMA CORP$173,000
+31.1%
41,903
+40.8%
0.24%
-56.9%
CDTX  CIDARA THERAPEUTICS INC$163,000
-25.9%
12,8120.0%0.22%
-75.6%
ACSF BuyAMERICAN CAP SR FLOATING LTD$155,000
+20.2%
15,457
+17.5%
0.21%
-60.4%
ASMB BuyASSEMBLY BIOSCIENCES INC$111,000
-18.4%
22,185
+22.6%
0.15%
-73.2%
SNTA BuySYNTA PHARMACEUTICALS CORPcall$16,000
-27.3%
67,000
+8.1%
0.02%
-76.1%
MDLY ExitMEDLEY MGMT INC$0–-32,893
-100.0%
-0.78%–
JRO ExitNUVEEN FLTNG RTE INCM OPP FD$0–-26,314
-100.0%
-1.08%–
FRA ExitBLACKROCK FLOAT RATE OME STR$0–-22,285
-100.0%
-1.20%–
PHD ExitPIONEER FLOATING RATE TR$0–-29,603
-100.0%
-1.35%–
NSL ExitNUVEEN SR INCOME FD$0–-72,363
-100.0%
-1.75%–
DNAI ExitPRONAI THERAPEUTICS INC$0–-45,719
-100.0%
-2.89%–
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2016-05-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MOLECULAR TEMPLATES INC24Q2 202330.7%
STRONGBRIDGE BIOPHARMA PLC22Q3 202173.1%
GARRISON CAP INC18Q3 20209.9%
BERKSHIRE HATHAWAY INC DEL17Q3 20195.8%
EIGER BIOPHARMACEUTICALS INC17Q3 20221.7%
AGILE THERAPEUTICS INC16Q1 201855.5%
KALA PHARNACEUTICALS INC16Q4 202117.6%
CM FIN INC16Q1 20197.8%
SYNTA PHARMACEUTICALS CORP15Q2 201699.9%
CTI BIOPHARMA CORP14Q4 20218.7%

View CAXTON CORP's complete holdings history.

Latest significant ownerships (13-D/G)
CAXTON CORP Q1 2016 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Addex Therapeutics Ltd.February 14, 2023718,8490.9%
Cardiff Oncology, Inc.February 14, 2023983,6072.2%
Rezolute, Inc.February 14, 20231,860,5185.0%
Xeris Biopharma Holdings, Inc.February 14, 20235,973,3244.4%
CTI BIOPHARMA CORPFebruary 14, 20222,239,3002.3%
Sierra Oncology, Inc.February 14, 20221,119,3227.0%
Strongbridge Biopharma plcSold outJanuary 05, 202200.0%
SUNESIS PHARMACEUTICALS INCSold outFebruary 16, 202100.0%
Alcentra Capital CorpFebruary 14, 20201,005,0007.8%
Garrison Capital Inc.February 14, 20201,223,0967.6%

View CAXTON CORP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-02-14
SC 13G/A2023-02-14
SC 13G/A2023-02-14

View CAXTON CORP's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (72465000.0 != 72463000.0)

Export CAXTON CORP's holdings

CSVXLS